Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

After over ten years’ of DARPA-funded research, and in collaboration with the NIH, Professor Kieran Clarke has exclusively licensed her novel ketone monoester, ΔG®, to Silicon Valley start-up company HVMN Inc. ΔG® will be used in the world’s first ketone drink for athletes (http://hvmn.com/ketone), for use in training, endurance performance and recovery after exercise.

Papers recently published in Cell Metabolism, FASEB, Frontiers in Physiology and Obesity have caused mounting anticipation of a commercially available product. Since the launch on Monday 6 November 2017, press coverage has been high on both sides of the Atlantic, with articles in The Times, The Independent, Business Insider and Men’s Health (amongst many others).

Professor Clarke continues to collaborate with the NIH and other institutions worldwide on potential applications of ΔG®, including for obesity, metabolic disease, type 2 diabetes and neurodegenerative diseases, such as Alzheimer’s and Parkinson’s. 

bottle.jpg

Similar stories

Researchers discover novel form of adaptation in the auditory system

DPAG’s auditory neuroscience researchers have found that the auditory system adapts to the changing acoustics of reverberant environments by temporally shifting the inhibitory tuning of cortical neurons to remove reverberation.

Collaborative team driven by DPAG and Chemistry awarded RSC Horizon Prize

The Molecular Flow Sensor Team, with collaborating members principally from DPAG’s Robbins and Talbot groups and the Department of Chemistry, has been named the winner of the Royal Society of Chemistry’s (RSC) Analytical Division Horizon Prize for the development of a new technology for measuring lung function.

REF 2021 results

Oxford Parkinson’s Disease Centre awarded £3.8 million to reveal the role of calcium in Parkinson’s

A collaborative research team led by the Oxford Parkinson’s Disease Centre (OPDC) has been awarded a £3.8 million Wellcome Trust Collaborative Award to study the function of calcium in dopamine neurons, and how this is plays a role in Parkinson’s. Their research will help explain how and why dopamine neurons are vulnerable in the disease and look at how they may be preserved.

The effect of nuclear pH on cardiac gene expression

Research led by Dr Alzbeta Hulikova and Professor Pawel Swietach has, for the first time, described the potential regulation of nuclear acid-base chemistry in neonatal and adult cardiomyocytes, and explained its relevance in the context of heart physiology and pathology.